Affymax gets $10M milestone, PDUFA date on anemia drug

Affymax ($AFFY) is pocketing a $10 million milestone from Takeda on the news that the FDA has accepted the NDA for the anemia treatment peginesatide, a drug formerly known as Hematide. Earlier today Affymax also noted that the FDA had assigned a March 27 action date for the drug. If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent available for anemia associated with CKD patients on dialysis in the United States. Release | Release

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.